A 38,753-patient cross-trial synthesis in Nature Medicine maps short-term safety of HF combination therapies—signaling how sponsors can use pooled...
A Nature Medicine RCT of allogeneic iPSC-derived cardiomyocytes in advanced ischemic heart failure just set the protocol bar for...
Cardior's CDR132L cleared safety hurdles in phase 2 but missed primary cardiac structure endpoints—a rigorous negative result that reshapes...
Low-dose digoxin cut hospitalizations but missed its primary endpoint in a 1,400-patient RCT—exposing a gap between statistical significance and...
